The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Role and mechanism of action of sclerostin in bone
Open accessAbstract
After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation. Dysregulation of sclerostin expression also underlies the pathophysiology of skeletal disorders characterized by loss of bone mass as well as the damaging effects of some cancers in bone. Thus, sclerostin has quickly become a promising molecular target for the treatment of osteoporosis and other skeletal diseases, and beneficial skeletal outcomes are observed in animal studies and clinical trials using neutralizing antibodies against sclerostin. However, the anabolic effect of blocking sclerostin decreases with time, bone mass accrual is also accompanied by anti-catabolic effects, and there is bone loss over time after therapy discontinuation. Further, the cellular source of sclerostin in the bone/bone marrow microenvironment under physiological and pathological conditions, the pathways that regulate sclerostin expression and the mechanisms by which sclerostin modulates the activity of osteocytes, osteoblasts, and osteoclasts remain unclear. In this review, we highlight the current knowledge on the regulation of Sost/sclerotin expression and its mechanism(s) of action, discuss novel observations regarding its role in signaling pathways activated by hormones and mechanical stimuli in bone, and propose future research needed to understand the full potential of therapeutic interventions that modulate Sost/sclerostin expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844 · cited 1×
“Osteoprotegerin (Opg), the decoy receptor for Rankl and thus inhibitor of bone resorption (88), is a Wnt/βcatenin target gene (1).”
Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 2×
“Previous work demonstrated that Sclerostin directly interacts with several members of the BMP and Wnt pathways such as BMP4, BMP2 and Lrp 4/5/6 (4;77;95;96).”
Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin
Robling, A. G., Niziolek, P. J., Baldridge, L. A., Condon, K. W., Allen, M. R., Alam, I., Mantila, S. M., Gluhak-Heinrich, J., Bellido, T. M., Harris, S. E., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705092200 · Cited by 1,350
Self-citationRomosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 4×
“Sclerostin is encoded by Sost, a gene identified through genetic linkage analyses in sclerosteosis and van Buchem’s disease patients (7;32).”
InfluentialOsteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Fogh, J., & Trempe, G. (1975) · Human Tumor Cells in Vitro · doi:10.1007/978-1-4757-1647-4_5 · Cited by 1,005
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
(1975) · Springer eBooks · doi:10.1007/978-1-4757-1647-4 · Cited by 756
Glucocorticoid-Induced Bone Disease
Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 694
Bellido, T., Ali, A. A., Gubrij, I., Plotkin, L. I., Fu, Q., O’Brien, C. A., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2005-0239 · Cited by 641
Self-citationSOST is a target gene for PTH in bone
Keller, H., & Kneissel, M. (2005) · Bone · doi:10.1016/j.bone.2005.03.018 · Cited by 616
Frost, H. M. (1987) · PubMed · Cited by 615
Essential role of β-catenin in postnatal bone acquisition.
Holmen, S. L., Zylstra, C. R., Mukherjee, A., Sigler, R. E., Faugere, M.-C., Bouxsein, M. L., Deng, L., Clemens, T. L., & Williams, B. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501900200 · Cited by 584
Osteocyte Wnt/β-Catenin Signaling Is Required for Normal Bone Homeostasis
Kramer, I., Halleux, C., Keller, H., Pegurri, M., Gooi, J. H., Weber, P. B., Feng, J. Q., Bonewald, L. F., & Kneissel, M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01428-09 · Cited by 567
Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805133106 · Cited by 556
Wnt/β-Catenin Signaling Is a Normal Physiological Response to Mechanical Loading in Bone
Robinson, J. A., Chatterjee-Kishore, M., Yaworsky, P. J., Cullen, D. M., Zhao, W., Li, C., Kharode, Y., Sauter, L., Babij, P., Brown, E. L., et al. (2006) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84086-3 · Cited by 521
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025900 · Cited by 503
Establishment of an osteocyte-like cell line, MLO-Y4
Kato, Y., Windle, J. J., Koop, B. A., Mundy, G. R., & Bonewald, L. F. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.12.2014 · Cited by 500
Tu, X., Rhee, Y., Condon, K. W., Bivi, N., Allen, M. R., Dwyer, D., Stolina, M., Turner, C. H., Robling, A. G., Plotkin, L. I., et al. (2012) · Bone · doi:10.1016/j.bone.2011.10.025 · Cited by 459
Self-citationMsx2 promotes cardiovascular calcification by activating paracrine Wnt signals
Shao, J.-S., Cheng, S.-L., Pingsterhaus, J. M., Charlton-Kachigian, N., Loewy, A. P., & Towler, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524140 · Cited by 452
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Ominsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G., Gong, J., Gao, Y., Cao, J., Graham, K., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.14 · Cited by 414
Function of osteocytes in bone
Aarden, E. M., Nijweide, P. J., & Burger, E. H. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240550304 · Cited by 409
Pathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men
Mödder, U. I., Hoey, K. A., Amin, S., McCready, L. K., Achenbach, S. J., Riggs, B. L., Melton, L. J., & Khosla, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.217 · Cited by 397
Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
O'Brien, C. A., Plotkin, L. I., Galli, C., Goellner, J. J., Gortazar, A. R., Allen, M. R., Robling, A. G., Bouxsein, M., Schipani, E., Turner, C. H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002942 · Cited by 390
Self-citationDynamics of the transition from osteoblast to osteocyte
Dallas, S. L., & Bonewald, L. F. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05246.x · Cited by 343
Xiong, J., Piemontese, M., Onal, M., Campbell, J., Goellner, J. J., Dusevich, V., Bonewald, L., Manolagas, S. C., & O’Brien, C. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138189 · Cited by 323
Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function
Leupin, O., Piters, E., Halleux, C., Hu, S., Kramer, I., Morvan, F., Bouwmeester, T., Schirle, M., Bueno-Lozano, M., Ramos Fuentes, F. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190330 · Cited by 301
Walker, E. C., McGregor, N. E., Poulton, I. J., Solano, M., Pompolo, S., Fernandes, T. J., Constable, M. J., Nicholson, G. C., Zhang, J.-G., Nicola, N. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40568 · Cited by 300
Pathogenesis of myeloma bone disease
Roodman, G. D. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22403 · Cited by 296
Staehling‐Hampton, K., Proll, S., Paeper, B. W., Zhao, L., Charmley, P., Brown, A., Gardner, J. C., Galas, D., Schatzman, R. C., Beighton, P., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10401 · Cited by 294
The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro
Spatz, J. M., Wein, M. N., Gooi, J. H., Qu, Y., Garr, J. L., Liu, S., Barry, K. J., Uda, Y., Lai, F., Dedic, C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.628313 · Cited by 290
Amrein, K., Amrein, S., Drexler, C., Dimai, H. P., Dobnig, H., Pfeifer, K., Tomaschitz, A., Pieber, T. R., & Fahrleitner-Pammer, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2152 · Cited by 277
Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone
Tu, X., Delgado-Calle, J., Condon, K. W., Maycas, M., Zhang, H., Carlesso, N., Taketo, M. M., Burr, D. B., Plotkin, L. I., & Bellido, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409857112 · Cited by 276
Self-citationZhu, D., Mackenzie, N. C. W., Millán, J. L., Farquharson, C., & MacRae, V. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019595 · Cited by 276
Kamiya, N., Ye, L., Kobayashi, T., Mochida, Y., Yamauchi, M., Kronenberg, H. M., Feng, J. Q., & Mishina, Y. (2008) · Development · doi:10.1242/dev.025825 · Cited by 275
Kusu, N., Laurikkala, J., Imanishi, M., Usui, H., Konishi, M., Miyake, A., Thesleff, I., & Itoh, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301716200 · Cited by 274
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Florio, M., Gunasekaran, K., Stolina, M., Li, X., Liu, L., Tipton, B., Salimi-Moosavi, H., Asuncion, F. J., Li, C., Sun, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms11505 · Cited by 257
Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice
Kramer, I., Loots, G. G., Studer, A., Keller, H., & Kneissel, M. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090730 · Cited by 247
Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription Factors
Leupin, O., Kramer, I., Collette, N. M., Loots, G. G., Natt, F., Kneissel, M., & Keller, H. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070804 · Cited by 246
Bonnet, N., Standley, K. N., Bianchi, E. N., Stadelmann, V., Foti, M., Conway, S. J., & Ferrari, S. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.060335 · Cited by 214
Delgado-Calle, J., Anderson, J., Cregor, M. D., Hiasa, M., Chirgwin, J. M., Carlesso, N., Yoneda, T., Mohammad, K. S., Plotkin, L. I., Roodman, G. D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1703 · Cited by 214
Self-citationPTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling
Rhee, Y., Allen, M. R., Condon, K., Lezcano, V., Ronda, A. C., Galli, C., Olivos, N., Passeri, G., O'Brien, C. A., Bivi, N., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.304 · Cited by 208
Self-citationChoi, H. Y., Dieckmann, M., Herz, J., & Niemeier, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007930 · Cited by 208
Osteocytic signalling pathways as therapeutic targets for bone fragility
Plotkin, L. I., & Bellido, T. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.71 · Cited by 206
Self-citationEstablishment of an Osteoid Preosteocyte-like Cell MLO-A5 That Spontaneously Mineralizes in Culture
Kato, Y., Boskey, A., Spevak, L., Dallas, M., Hori, M., & Bonewald, L. F. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.9.1622 · Cited by 205
Effects of PTH on osteocyte function
Bellido, T., Saini, V., & Pajevic, P. D. (2013) · Bone · doi:10.1016/j.bone.2012.09.016 · Cited by 196
Padhi, D., Allison, M., Kivitz, A. J., Gutierrez, M. J., Stouch, B., Wang, C., & Jang, G. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.239 · Cited by 185
Terpos, E., Christoulas, D., Katodritou, E., Bratengeier, C., Gkotzamanidou, M., Michalis, E., Delimpasi, S., Pouli, A., Meletis, J., Kastritis, E., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27342 · Cited by 184
Biphasic and Dosage-Dependent Regulation of Osteoclastogenesis by β-Catenin
Wei, W., Zeve, D., Suh, J. M., Wang, X., Du, Y., Zerwekh, J. E., Dechow, P. C., Graff, J. M., & Wan, Y. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05980-11 · Cited by 181
Vincent, C., Findlay, D. M., Welldon, K. J., Wijenayaka, A. R., Zheng, T. S., Haynes, D. R., Fazzalari, N. L., Evdokiou, A., & Atkins, G. J. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090305 · Cited by 180
Cohen-Kfir, E., Artsi, H., Levin, A., Abramowitz, E., Bajayo, A., Gurt, I., Zhong, L., D'Urso, A., Toiber, D., Mostoslavsky, R., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1128 · Cited by 179
Tanaka, K.-I., Yamaguchi, T., Kanazawa, I., & Sugimoto, T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.091 · Cited by 178
Saini, V., Marengi, D. A., Barry, K. J., Fulzele, K. S., Heiden, E., Liu, X., Dedic, C., Maeda, A., Lotinun, S., Baron, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.441360 · Cited by 167
Brandenburg, V. M., Kramann, R., Koos, R., Krüger, T., Schurgers, L., Mühlenbruch, G., Hübner, S., Gladziwa, U., Drechsler, C., & Ketteler, M. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-219 · Cited by 160
Ardawi, M. M., Rouzi, A. A., Al-Sibiani, S. A., Al-Senani, N. S., Qari, M. H., & Mousa, S. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1718 · Cited by 148
Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction
Wehmeyer, C., Frank, S., Beckmann, D., Böttcher, M., Cromme, C., König, U., Fennen, M., Held, A., Paruzel, P., Hartmann, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4351 · Cited by 141
Targeted deletion of Sost distal enhancer increases bone formation and bone mass
Collette, N. M., Genetos, D. C., Economides, A. N., Xie, L., Shahnazari, M., Yao, W., Lane, N. E., Harland, R. M., & Loots, G. G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207188109 · Cited by 140
Sclerostin in Mineralized Matrices and van Buchem Disease
van Bezooijen, R. L., Bronckers, A. L. J. J., Gortzak, R. A. T., Hogendoorn, P. C. W., van der Wee-Pals, L. J. A., Balemans, W., Oostenbroek, H. J., Hul, W. V., Hamersma, H. A., Dikkers, F. G., et al. (2009) · Journal of Dental Research · doi:10.1177/0022034509338340 · Cited by 140
DNA methylation contributes to the regulation of sclerostin expression in human osteocytes
Delgado‐Calle, J., Sañudo, C., Bolado‐Carrancio, A., Fernández, A. F., Arozamena, J., Pascual-Carra, M. A., Rodríguez-Rey, J. C., Fraga, M. F., Bonewald, L. F., & Riancho, J. A. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1491 · Cited by 139
Self-citationSato, A. Y., Cregor, M. D., Delgado‐Calle, J., Condon, K. W., Allen, M. R., Peacock, M., Plotkin, L. I., & Bellido, T. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2869 · Cited by 136
Self-citationBalemans, W., van den Ende, J., Paes-Alves, A. F., Dikkers, F. G., Willems, P. J., Vanhoenacker, F. M. H. M., de Melo, N. A., Alves, C. F., Stratakis, C. A., Hill, S. C., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302416 · Cited by 135
Myeloma cells suppress osteoblasts through sclerostin secretion
Colucci, S. C., Brunetti, G., Oranger, A., Mori, G., Sardone, F., Specchia, G., Rinaldi, E., Curci, P., Liso, V., Passeri, G., et al. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.22 · Cited by 130
Chang, M.-K., Krämer, I., Huber, T., Kinzel, B., Guth, S., Leupin, O., & Kneissel, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413828111 · Cited by 127
Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy
Moe, S. M., Chen, N. X., Newman, C. L., Organ, J. M., Kneissel, M., Krämer, I., Gattone, V. H., & Allen, M. R. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2372 · Cited by 125
Roforth, M. M., Fujita, K., McGregor, U. I., Kirmani, S., McCready, L. K., Peterson, J. M., Drake, M. T., Monroe, D. G., & Khosla, S. (2013) · Bone · doi:10.1016/j.bone.2013.10.019 · Cited by 121
Yao, W., Dai, W., Jiang, L., Lay, E. Y.-A., Zhong, Z. A., Ritchie, R. O., Li, X., Ke, H. Z., & Lane, N. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3308-6 · Cited by 119
Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts
Genetos, D. C., Toupadakis, C. A., Raheja, L. F., Wong, A., Papanicolaou, S. E., Fyhrie, D. P., Loots, G. G., & Yellowley, C. E. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22559 · Cited by 118
Delgado-Calle, J., Tu, X., Pacheco-Costa, R., McAndrews, K., Edwards, R., Pellegrini, G. G., Kuhlenschmidt, K., Olivos, N., Robling, A., Peacock, M., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3011 · Cited by 114
Self-citationBen-awadh, A. N., Delgado-Calle, J., Tu, X., Kuhlenschmidt, K., Allen, M. R., Plotkin, L. I., & Bellido, T. (2014) · Endocrinology · doi:10.1210/en.2014-1046 · Cited by 114
Self-citationMendoza-Villanueva, D., Zeef, L. A. H., & Shore, P. (2011) · Breast Cancer Research · doi:10.1186/bcr3048 · Cited by 107
Stolina, M., Dwyer, D., Niu, Q., Villasenor, K. S., Kurimoto, P., Grisanti, M. S., Han, C.-Y. E., Liu, M., Li, X., Ominsky, M. S., et al. (2014) · Bone · doi:10.1016/j.bone.2014.07.031 · Cited by 100
Urano, T., Shiraki, M., Ouchi, Y., & Inoue, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1218 · Cited by 100
Eda, H., Santo, L., Wein, M. N., Hu, D. Z., Cirstea, D. D., Nemani, N., Tai, Y., Raines, S. E., Kuhstoss, S. A., Munshi, N. C., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2789 · Cited by 100
Galea, G. L., Sunters, A., Meakin, L. B., Zaman, G., Sugiyama, T., Lanyon, L. E., & Price, J. S. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.06.019 · Cited by 99
Koos, R., Brandenburg, V. M., Mahnken, A. H., Schneider, R. K., Dohmen, G., Autschbach, R., Marx, N., & Kramann, R. (2013) · PubMed · Cited by 96
Kim, S. J., Biegański, T., Sohn, Y. B., Kozlowski, K. S., Semënov, M. V., Okamoto, N., Kim, C. H., Ko, A., Ahn, G., Choi, Y., et al. (2011) · Human Genetics · doi:10.1007/s00439-011-0947-3 · Cited by 94
Clinical utility of serum sclerostin measurements
Clarke, B. L., & Drake, M. T. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.95 · Cited by 92
Roudier, M. P., Li, X., Niu, Q., Pacheco, E., Pretorius, J. K., Graham, K. C., Yoon, B. P., Gong, J., Warmington, K. S., Ke, H. Z., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37802 · Cited by 89
Absence of sclerostin adversely affects B-cell survival
Cain, C. J., Rueda, R., McLelland, B. T., Collette, N. M., Loots, G. G., & Manilay, J. O. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1608 · Cited by 89
Sclerostin is overexpressed by plasma cells from multiple myeloma patients
Brunetti, G., Oranger, A., Mori, G., Specchia, G., Rinaldi, E., Curci, P., Zallone, A. Z., Rizzi, R., Grano, M., & Colucci, S. C. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06196.x · Cited by 85
Fijałkowski, I., Geets, E., Steenackers, E., Hoof, V. O. V., Ramos, F. J., Mortier, G. R., Fortuna, A. M., Hul, W. V., & Boudin, E. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2782 · Cited by 85
Matrix Mineralization as a Trigger for Osteocyte Maturation
Irie, K., Ejiri, S., Sakakura, Y., Shibui, T., & Yajima, T. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.950527 · Cited by 82
Sclerostin Enhances Adipocyte Differentiation in 3T3‐L1 Cells
浮田, 万., Yamaguchi, T., Ohata, N., & Tamura, M. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25432 · Cited by 81
Sclerostin Inhibition in the Management of Osteoporosis
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0126-6 · Cited by 78
A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures
Gori, F., Lerner, U. H., Ohlsson, C., & Baron, R. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.36 · Cited by 77
Recknor, C., Recker, R., Benson, C. T., Robins, D., Chiang, A. Y., Alam, J., Hu, L.-J., Matsumoto, T., Sowa, H., Sloan, J. H., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2489 · Cited by 77
Greenberg, A. J., Rajkumar, S. V., Therneau, T., Singh, P. P., Dispenzieri, A. A., & Kumar, S. K. (2013) · Leukemia · doi:10.1038/leu.2013.258 · Cited by 75
Marenzana, M., Greenslade, K. J., Eddleston, A., Okoye, R., Marshall, D. R., Moore, A., & Robinson, M. K. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30385 · Cited by 73
Ota, K., Quint, P. S., Ruan, M. M., Pederson, L. G., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24537 · Cited by 70
Robling, A. G., Kedlaya, R., Ellis, S. N., Childress, P., Bidwell, J. P., Bellido, T., & Turner, C. H. (2011) · Endocrinology · doi:10.1210/en.2011-0049 · Cited by 69
Self-citationJäger, A., Götz, W., Lossdörfer, S., & Rath-Deschner, B. (2009) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2009.01227.x · Cited by 67
Kim, R. Y., Yang, H. J., Song, Y. M., Kim, I. S., & Hwang, S. J. (2015) · Tissue Engineering Part A · doi:10.1089/ten.tea.2014.0585 · Cited by 64
TGF-β regulates sclerostin expression via the ECR5 enhancer
Loots, G. G., Keller, H., Leupin, O., Murugesh, D. K., Collette, N. M., & Genetos, D. C. (2011) · Bone · doi:10.1016/j.bone.2011.11.016 · Cited by 62
Sclerostin Deficiency Is Linked to Altered Bone Composition
Hassler, N., Roschger, A., Gamsjaeger, S., Krämer, I., Lueger, S., van Lierop, A. H., Roschger, P., Klaushofer, K., Paschalis, E. P., Kneissel, M., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2259 · Cited by 60
He, J., Genetos, D. C., Yellowley, C. E., & Leach, J. K. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22514 · Cited by 58
Klangjareonchai, T., Nimitphong, H., Saetung, S., Bhirommuang, N., Samittarucksa, R., Chanprasertyothin, S., Sudatip, R., & Ongphiphadhanakul, B. (2014) · International Journal of Endocrinology · doi:10.1155/2014/261545 · Cited by 56
Rhee, Y., Lee, E.-Y., Lezcano, V., Ronda, A. C., Condon, K. W., Allen, M. R., Plotkin, L. I., & Bellido, T. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.485938 · Cited by 55
Self-citationEffect of supplemental vitamin D and calcium on serum sclerostin levels
Dawson-Hughes, B. F., Harris, S. S., Ceglia, L., & Palermo, N. J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0862 · Cited by 54
Maycas, M., McAndrews, K., Sato, A. Y., Pellegrini, G., Brown, D. M., Allen, M. R., Plotkin, L. I., Gortázar, A. R., Esbrit, P., & Bellido, T. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3007 · Cited by 54
Self-citationSclerostin is a direct target of osteoblast-specific transcription factor osterix
Yang, F., Tang, W., So, S., Crombrugghe, B. D., & Zhang, C. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.128 · Cited by 53
Wang, Q., & Wolf, N. S. (1990) · PubMed · Cited by 49
Class I and IIa Histone Deacetylases Have Opposite Effects on Sclerostin Gene Regulation
Baertschi, S., Baur, N., Lueders-Lefevre, V., Voshol, J., & Keller, H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564997 · Cited by 48
Osteocyte Deficiency in Hip Fractures
Delgado‐Calle, J., Arozamena, J., García-Renedo, R. J., García‐Ibarbia, C., Pascual-Carra, M. A., González-Macías, J., & Riancho, J. A. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9522-0 · Cited by 43
Self-citationThe sclerostin-bone protein interactome
Ketha, H., Craig, T. A., Madden, B. J., Bergen, H. R., & Kumar, R. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.048 · Cited by 42
New insights into the location and form of sclerostin
Hernández, P., Whitty, C., Wardale, R. J., & HENSON, F. M. D. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.079 · Cited by 40
Two cases of Van Buchem's disease.
Dixon, J. M., Cull, R. E., & Gamble, P. (1982) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.45.10.913 · Cited by 38
Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids
García-Fontana, B., Morales, S., Varsavsky, M., García‐Martin, A., Garcia-Salcedo, J. A., Reyes‐García, R., & Muñoz‐Torres, M. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2462-y · Cited by 38
The Role of DNA Methylation in Common Skeletal Disorders
Delgado‐Calle, J., & Riancho, J. A. (2012) · Biology · doi:10.3390/biology1030698 · Cited by 33
Self-citationGlucocorticoids are not always deleterious for bone
van Lierop, A. H., Hamdy, N. A. T., & Papapoulos, S. E. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.151 · Cited by 31
Emerging Therapies for Osteoporosis
McClung, M. R. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.4.429 · Cited by 30
Delgado‐Calle, J., Arozamena, J., Pérez-López, J., Bolado‐Carrancio, A., Sañudo, C., Agudo, G., de la Vega, R., Alonso, M. A., Rodríguez-Rey, J. C., & Riancho, J. A. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.02.002 · Cited by 28
Self-citationNitric Oxide is Involved in the Down-regulation of SOST Expression Induced by Mechanical Loading
Delgado‐Calle, J., Riancho, J. A., & Klein‐Nulend, J. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9821-8 · Cited by 27
Self-citationHigh Bone Mass–Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo
Niziolek, P., MacDonald, B. T., Kedlaya, R., Zhang, M., Bellido, T., He, X., Warman, M. L., & Robling, A. G. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2514 · Cited by 27
Self-citationNisio, A. D., Toni, L. D., Speltra, E., Rocca, M. S., Taglialavoro, G., Ferlin, A., & Foresta, C. (2015) · Endocrinology · doi:10.1210/en.2015-1244 · Cited by 25
Effect of Vitamin D Treatment on Serum Sclerostin Level
Acıbucu, F., Dökmetaş, H. S., Acıbucu, D., Kılıçlı, F., Aydemir, M., & Çakmak, E. (2016) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0035-1559790 · Cited by 25
Çidem, M., Karacan, İ., Arat, N. B., Zengi, O., Özkaya, M., Güzel, S. P., Özkan, C., & Beytemür, O. (2015) · Rheumatology International · doi:10.1007/s00296-015-3294-1 · Cited by 22
Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoids
Warriner, A. H., & Saag, K. G. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/01.med.0000436249.84273.7b · Cited by 21
Fujiwara, M., Kubota, T., Wang, W. J., Ohata, Y., Miura, K., Kitaoka, T., Okuzaki, D., Namba, N., Michigami, T., Kitabatake, Y., et al. (2016) · Bone · doi:10.1016/j.bone.2016.01.024 · Cited by 19
Early response of the human SOST gene to stimulation by 1α,25-dihydroxyvitamin D3
Wijenayaka, A. R., Prideaux, M., Yang, D., Morris, H. A., Findlay, D. M., Anderson, P., & Atkins, G. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.12.006 · Cited by 18
John, H. C. S., Hansen, S. J., & Pike, J. W. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.09.005 · Cited by 15
The systemic effects of sclerostin overexpression using ΦC31 integrase in mice
Zhang, D., Park, B. M., Kang, M., Nam, H. J., Kim, E. J., Bae, C. H., & Lim, S. K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.178 · Cited by 10
Cited by
Vlashi, R., Zhang, X., Wu, M., & Chen, G. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.011 · Cited by 165
The Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
Bone diseases in patients with chronic liver disease
Jeong, H., & Kim, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174270 · Cited by 113
Sebastiani, P., Federico, A., Morris, M., Gurinovich, A., Tanaka, T., Chandler, K. B., Andersen, S. L., Denis, G., Costello, C. E., Ferrucci, L., et al. (2021) · Aging Cell · doi:10.1111/acel.13290 · Cited by 103
High-density lipoprotein (HDL) metabolism and bone mass
Papachristou, N. I., Blair, H. C., Kypreos, K. E., & Papachristou, D. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0657 · Cited by 94
Metadata
- Authors
- Delgado-Calle, J., Sato, A. Y., & Bellido, T.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 96
- Pages
- 29-37
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2531652035
- Cited by
- 443
- References
- 129
- FWCI
- 25.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.